Polaris Partners

Polaris Partners is a venture capital firm based in Boston, Massachusetts, with offices in San Francisco. Founded in 1996, it targets investments in technology and life science companies across the United States and Europe, supporting startups from early formation to profitable growth. The firm's healthcare and biotechnology focus encompasses digital health, consumer-centric care delivery, patient-provider solutions, data science and analytics, as well as therapeutics, genomics and other life science platforms. It backs companies across business-to-business and business-to-consumer models, software as a service, healthcare information technology and health tech sectors, partnering with repeat entrepreneurs to build durable, scale-ready businesses.

Marissa Bertorelli

Principal

Mary Blair

CFO

Alexandra Cantley Ph.D

Partner

Darren Carroll

Partner

Brian Chee

Managing Partner

Jonathan Flint JD

Founding Partner

John Gannon

CFO and Partner

Nil Gural

Senior Associate

Paulina Hill

Principal

Mark Jacobson

Principal

Rahul Kakkar

Entrepreneur Partner

Pat Kinsel

Partner

Dan Lombard

Managing Partner

Ellie McGuire

Partner

Terry McGuire

Partner

Eileen McGuire

Partner

Sabrina Chiasson

Partner

Pat Mulach

Vice President

Amir Nashat

Managing Partner

Kim Png Ph.D

Principal

Noel Ruane

Venture Partner

Amy Schulman

Managing Partner

Gary Swart

General Partner

Jim Weinstein

Entrepreneur Partner

Bryce Youngren

Managing Partner

738 past transactions

Auron Therapeutics

Series B in 2025
Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Leyden Labs

Series B in 2025
Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.

FIRE1

Venture Round in 2025
FIRE1 is an Irish-based company specializing in the development of innovative therapeutic devices. Its flagship product is a remote monitoring system designed to enhance heart failure patients' lives by providing real-time data to healthcare providers, facilitating early detection and proactive interventions.

Noema Pharma

Series B in 2024
Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

TRex Bio

Series B in 2024
TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Sunbird Bio

Venture Round in 2024
Sunbird Bio is a diagnostics platform developer focused on advancing molecular diagnostics to deliver faster and more accurate results. Founded by Huilin Shao, the company specializes in detecting a wide array of diseases, including infectious diseases, neurodegenerative disorders, and cancer. By enabling early diagnosis, Sunbird Bio aims to enhance healthcare outcomes and support physicians in making informed decisions. The platform is designed to improve clarity and accessibility in diagnostic testing, thereby contributing to better patient care.

Noetik

Series A in 2024
Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By harnessing self-supervised learning and integrating diverse human multimodal data, the company aims to enhance the precision and effectiveness of immunotherapies. This approach enables the development of more personalized cancer treatments, contributing to the advancement of targeted therapies in oncology.

BeMe Health

Seed Round in 2024
BeMe Health is a mobile platform dedicated to supporting the mental health and emotional well-being of teenagers. It offers curated content, learning opportunities, and live coaching connections.

ByHeart

Venture Round in 2024
Founded in 2016, ByHeart is a New York-based company dedicated to producing evolved infant nutrition products. It translates leading scientific research into innovative foods and formulas that prioritize immune, microbiome, cognitive, and digestive health.

Lore

Series A in 2024
Lore Health is a startup that combines artificial intelligence (AI) technology with social media to build a welcoming, encouraging, and judgment-free community where individuals may meet others who share their interests.

Livara Health

Series B in 2024
Livara Health specializes in non-invasive, personalized treatment for musculoskeletal conditions. Its platform offers a data-driven six-week program for back pain relief, customized based on patient assessment, along with coaching support.

Delphia Therapeutics

Series A in 2024
Delphia Therapeutics, headquartered in Boston, USA, is a biotechnology company focused on cancer therapeutics. It operates a laboratory dedicated to studying cancer-driving pathways and developing treatments that target and over-activate specific cancer-linked cell signaling, ultimately leading to the death of tumor cells.

Capstan Therapeutics

Series B in 2024
Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

Matter Neuroscience

Seed Round in 2024
Over millions and millions of years, a collection of reward systems

Freenome

Series E in 2024
Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Cohere Health

Series C in 2024
Founded in 2019 and based in Boston, Cohere Health is a healthcare technology company dedicated to enhancing efficiency and effectiveness within the healthcare system. It achieves this by leveraging technology to simplify processes, improve communication among stakeholders, and ultimately optimize patient outcomes.

Vico Therapeutics

Series B in 2024
Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

UpDoc

Seed Round in 2024
UpDoc is a technology-enabled services firm that offers the world's first unique conversational AI platform for autonomous prescription management.

Lyndra Therapeutics

Series E in 2023
Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Tome Biosciences

Series A in 2023
Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

Seismic Therapeutic

Series B in 2023
Seismic Therapeutic is a biotechnology company focused on advancing immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its proprietary IMPACTâ„¢ platform, Seismic Therapeutic addresses critical challenges in the development of biologics by combining machine learning with structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies for patients more efficiently. The company is developing a pipeline of biologics specifically targeting adaptive immune system dysregulation to treat various autoimmune diseases.

Sovato

Seed Round in 2023
Sovato Health specializes in remote surgical access, offering a platform that connects skilled surgeons with patients in underserved areas. This platform integrates people, systems, tools, data, and business models to ensure safe, scalable, and sustainable remote surgical procedures.

Engine Biosciences

Series A in 2023
Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Triveni Bio

Series A in 2023
Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

65LAB

Seed Round in 2023
65LAB is a biotechnology company that specializes in accelerating the development of innovative therapies. It operates an accelerator program designed to commercialize promising therapeutic projects. The company identifies potential therapies from applicants, provides funding and mentoring, and helps these projects achieve preclinical proof-of-concept.

Best Doctors

Venture Round in 2023
Best Doctors offers an innovative employee health benefit that provides access to global medical expertise for confident healthcare decisions. When facing significant medical choices, members can consult with leading specialists worldwide to ensure accurate diagnoses and appropriate treatments.

Contact Networks

Venture Round in 2023
Contact Networks offers Enterprise Relationship Management (ERM) software solutions designed to help professional services firms maximize the value of their relationship networks for business development. Their flagship product, ContactNet, is an automated search application that quickly identifies employees with strong relationships to a client or prospect. Based in Boston, MA, Contact Networks was acquired by Thomson Reuters in 2007.

Centra Software

Venture Round in 2023
The Company offers infrastructure for comprehensive live collaboration including voice over the internet.

CyberSafe

Venture Round in 2023
CyberSafe is an internet security company that provides Kerberos-based security solutions for SAP business applications. Its products include ActiveTRUST Security Software, TrustBroker Security Suite, Defensor, and Centrax, designed to enable secure electronic transactions and reduce administration costs. The company also provides consulting services for enterprise security deployment, including security assessments, architecture development, network security implementation and integration, security training, and technical support. Founded in 1991 and headquartered in Issaquah, Washington, CyberSafe focuses on helping organizations secure electronic business operations while optimizing security administration.

Tausight

Venture Round in 2023
Founded in 2018, Tausight is a technology company based in Sudbury, Massachusetts with an additional office in San Francisco. It specializes in developing software to reduce healthcare cyber incidents involving patient data theft.

Simon Data

Series D in 2023
Simon Data develops a customer data platform designed to enhance campaign performance via precise segmentation and personalization. Its platform identifies purchase intent, predicts churn, estimates customer lifetime value, and enables brands to deliver personalized experiences across channels.

Vytyl Health Management

Venture Round in 2023
Vita Health operates an online mental health care platform focused on providing high-quality treatment for adolescents and transitional age youth. The platform enables patients to receive quick and accessible care from licensed therapists through telehealth services. It addresses various mental health challenges, including anxiety, depression, and suicidal ideation, ensuring that young individuals can conveniently access the support they need from the comfort of their homes.

Tisento Therapeutics

Series A in 2023
Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to treat mitochondrial diseases, both in the central nervous system and peripherally, by targeting key aspects of the disease's pathophysiology, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. This approach enables patients to receive treatment promptly.

Engine Biosciences

Series A in 2023
Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

EpiBiologics

Series A in 2023
EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.

Crossbow Therapeutics

Series A in 2023
Crossbow Therapeutics is a biotechnology company focused on developing innovative cancer treatments. The company engineers antibodies to mimic T-cells, which are essential components of the immune system, aiming to enhance the quality of life for cancer patients. Their next-generation immunotherapies are designed to target previously unreachable cancer cell proteins with high precision, offering an efficient and selective approach to cancer treatment. By unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies, Crossbow Therapeutics seeks to dramatically expand the capabilities of antibody therapy across various cancer types, ultimately improving patient outcomes.

Lyndra Therapeutics

Series D in 2023
Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Candesant Biomedical

Series B in 2023
Candesant Biomedical, Incorporated is a medical device company focused on developing innovative solutions for excessive sweating and hyperhidrosis. Founded in 2015 and based in San Francisco, California, the company offers a proprietary device known as CDX-101, which utilizes water-activated technology to target and inactivate active sweat glands without causing discomfort to patients. The technology operates on the principle that alkali metals generate energy upon contact with water, allowing for precise energy delivery to the specific areas where sweat glands are most active. This approach not only aims to reduce excessive sweating but also helps inhibit bacterial growth associated with hyperhidrosis, providing a significant improvement in the quality of life for affected individuals.

Larkspur Biosciences

Series A in 2023
Larkspur Biosciences specializes in developing precision immunotherapies for specific patient groups with molecularly defined cancers. Its focus is on targeting the interaction between tumors and the immune system to stimulate robust, long-lasting responses.

EpiBiologics

Series A in 2023
EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.

QurAlis Corporation

Series B in 2023
QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Noema Pharma

Series B in 2023
Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Volastra

Series A in 2023
Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Paratus Sciences

Series A in 2023
Paratus Sciences focuses on advancing human health and health security by studying the biology of bats. It integrates cell biology, genomics, informatics, and large-scale data inputs to compare disease resistance patterns in bats with those in humans, aiming to develop therapeutics that mimic bats' adaptations.

Faro Health

Series A in 2023
Faro Health develops a cloud-based medical platform that standardizes, automates, and streamlines clinical trial processes. Its system handles administrative burdens, allowing clinical researchers to focus on critical decisions that drive clinical value.

August Bioservices

Series B in 2022
August Bioservices, LLC is a contract development and manufacturing organization (CDMO) based in Nashville, Tennessee, with an additional office in Celina, Tennessee. Established in 2017, the company specializes in offering a wide range of services for drug discovery, pharmaceutical development, and clinical manufacturing. Its research services encompass target validation, functional characterization, assay development, drug discovery, protein engineering, and both in vitro and in vivo testing. In the pharmaceutical development arena, August Bioservices provides formulation, process design, optimization, scale-up, and analytical method development. The company's clinical manufacturing capabilities include clinical trial supply, cGMP non-sterile and bulk manufacturing, aseptic fill and finish, and quality control. Additionally, it offers various testing services, such as pregnancy testing and viral disease testing, to clients in the pharmaceutical and biotechnology sectors. August Bioservices was previously known as PMI BioPharma Solutions until its name change in July 2020.

Jnana Therapeutics

Series C in 2022
Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Folx Health

Series B in 2022
Folx Health is a Boston-based telehealth platform founded in 2020, specializing in digital healthcare services tailored for the LGBTQIA+ community. It offers access to queer and trans clinicians, focusing on gender-affirming hormone therapy, sexual health, and family creation services.

Neumora Therapeutics

Series B in 2022
Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

CoV Biotechnology

Seed Round in 2022
CoV Biotechnology is an early-stage biotechnology company dedicated to addressing the challenges posed by the evolving and mutating nature of coronaviruses. The company develops booster vaccines and therapeutics specifically designed to combat variants of the SARS-2 beta coronavirus. By focusing on creating vaccines that offer broad-spectrum protection against both current and future variants, as well as potential zoonotic crossovers from animals to humans, CoV Biotechnology aims to provide effective solutions to enhance immunity and reduce the impact of future coronavirus pandemics.

Capstan Therapeutics

Series A in 2022
Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

Amplifire

Acquisition in 2022
Amplifire offers an online learning platform that combines adaptive learning with knowledge analytics and diagnostic capabilities to improve performance across education, healthcare, and corporate markets. The platform serves multiple industries, including medical, public sector, education, life sciences, accounting, and general corporate applications, delivering personalized, industry-tailored learning that yields measurable results and enhances job skills and organizational performance in competitive environments.

CAMP4 Therapeutics

Series B in 2022
CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Auron Therapeutics

Series A in 2022
Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Nomad Health

Venture Round in 2022
Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Foresight Mental Health

Series C in 2022
Foresight Mental Health is a technology-enabled psychiatry and therapy services company that directly employs psychiatrists, therapists, and psychiatric nurse practitioners to treat patients in its clinics. The company develops technology in collaboration with its providers, leveraging software and biomedical engineering to enhance care. Through a network of clinics, it offers a broad range of mental health treatments and wellness services and maintains patient profiles and a repository of scientific research and clinical information, including genetic profiles, comprehensive symptom profiles, and brain-chemical balance estimates to inform personalized care.

Scholar Rock

Post in 2022
Scholar Rock is a biopharmaceutical company dedicated to discovering and developing innovative therapies targeting dysregulated growth factors in disease microenvironments. Its proprietary platform enables the creation of monoclonal antibodies that selectively modulate these proteins at the cellular level, potentially avoiding historical challenges associated with inhibiting growth factors. The company's lead product candidate, SRK-015, is a selective inhibitor of myostatin activation for treating neuromuscular disorders like spinal muscular atrophy.

Tessa Therapeutics

Series A in 2022
Tessa Therapeutics specializes in developing immunotherapies for solid tumors. Its platform focuses on redirecting the body's antiviral immune response to recognize and kill cancer cells, offering new treatment options for patients.

Podimetrics

Series C in 2022
Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

TRex Bio

Series A in 2022
TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Satellite Bio

Series A in 2022
Satellite Bio develops cell therapies and regenerative medicine approaches, spanning cell biology, tissue engineering, and synthetic biology. The company focuses on proprietary, off-the-shelf implantable satellite organs that function as living therapeutic systems to replace or augment critical organ functions in patients with serious diseases, enabling medical professionals to address conditions arising from genetic and environmental factors. Its platform supports the development of modular, scalable therapies aimed at treating complex diseases and transforming patient outcomes.

Kallyope

Series D in 2022
Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Seismic Therapeutic

Series A in 2022
Seismic Therapeutic is a biotechnology company focused on advancing immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its proprietary IMPACTâ„¢ platform, Seismic Therapeutic addresses critical challenges in the development of biologics by combining machine learning with structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies for patients more efficiently. The company is developing a pipeline of biologics specifically targeting adaptive immune system dysregulation to treat various autoimmune diseases.

Dewpoint Therapeutics

Series C in 2022
Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

76Bio

Venture Round in 2022
Founded in 2020, 76Bio is a biotechnology company dedicated to developing innovative therapies for patients with life-threatening diseases. It specializes in pioneering targeted protein degraders.

Ankyra

Series B in 2021
Ankyra is a biotech company focused on developing anchored immunotherapy to enhance cancer treatment. The company's innovative approach addresses the challenges associated with traditional cytokine therapeutics, which often face limitations due to widespread immune activation and toxicity when administered systemically. Ankyra utilizes its Anchored Immunotherapy Platform to create ANK-101, a stable complex that combines a modified IL-12 cytokine with an FDA-approved adjuvant, aluminum hydroxide, which helps to retain the cytokine's potent activity at the tumor site. This localized delivery results in targeted inflammation that activates an anti-tumor immune response while minimizing adverse effects. Ankyra aims to optimize the efficacy and safety of its therapies, ultimately improving treatment outcomes for cancer patients.

Cardurion Pharmaceuticals

Venture Round in 2021
Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Sonrai Security

Series C in 2021
Sonrai Security provides a comprehensive enterprise identity and data governance platform for AWS, Azure, Google Cloud, and Kubernetes. Its flagship product, Dig, uses advanced graph technology to identify and monitor relationships between identities and data within public clouds. The platform automates workflows, remediation, and prevention capabilities across cloud and security teams, ensuring end-to-end security.

Neumora Therapeutics

Series A in 2021
Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

Nomad Health

Series D in 2021
Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Jnana Therapeutics

Series B in 2021
Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

ByHeart

Series B in 2021
Founded in 2016, ByHeart is a New York-based company dedicated to producing evolved infant nutrition products. It translates leading scientific research into innovative foods and formulas that prioritize immune, microbiome, cognitive, and digestive health.

FloQast

Series D in 2021
FloQast is a software company specializing in financial close management. It offers tools to streamline the month-end close process, improve collaboration among accounting teams, and enhance accuracy in financial reporting. FloQast's platform provides features such as task management, documentation, reconciliation, and reporting, integrating with various accounting systems like QuickBooks, NetSuite, and SAP.

OM1

Series D in 2021
OM1 is a digital health company that provides an outcome management platform for healthcare organizations to measure, forecast, and compare patient outcomes. Its platform aggregates and analyzes clinical and patient-reported data to meet outcomes requirements in value-based care programs, CMS bundles, and private arrangements. The solution uses predictive and prescriptive analytics to identify risks, cost drivers, and opportunities to improve clinical and financial performance across the care continuum. By delivering AI-driven insights, OM1 helps hospitals and health systems demonstrate outcomes to stakeholders, support benchmarking and decision-making, and drive more precise care management. The company also maintains specialized registries for collaborations, including systemic lupus erythematosus, to support research and performance improvement. Through gathering and enriching diverse clinical data, OM1 aims to establish a higher standard for health outcomes information and enable more informed, value-based care.

Muna Therapeutics

Series A in 2021
Muna Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies aimed at slowing or halting devastating neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.

Wellthy

Series B in 2021
Wellthy, Inc. is a family care concierge service based in New York, established in 2014. The company specializes in assisting individuals and families managing complex care situations, particularly those involving chronic illnesses, aging-related issues, or disabilities. Wellthy connects families with dedicated Care Coordinators who help navigate the logistical and administrative challenges of caregiving. This includes organizing appointments, managing contacts, and storing essential documents. The service is designed to support families dealing with a range of health conditions, such as dementia, diabetes, heart disease, and cancer, as well as those requiring assistance with childcare and special needs. Through its platform, Wellthy aims to alleviate the burden of care management, allowing families to focus on their loved ones’ well-being.

CubicPV

Venture Round in 2021
CubicPV is a solar manufacturing company that focuses on producing wafers and tandem modules using advanced silicon and perovskite technologies. The company develops innovative semiconductor combinations for tandem modules, which enhance energy harvesting by utilizing two different light absorbers, thus improving efficiency across a broader spectrum of sunlight. This technology aims to reduce the cost of solar electricity to be competitive with conventional energy sources, such as coal. By manufacturing silicon wafers directly from the silicon melt, CubicPV streamlines the production process, eliminating several steps and effectively doubling the yield. This approach not only lowers the cost of clean electricity but also minimizes the carbon footprint associated with solar panel production, supporting the growing global demand for sustainable energy solutions.

Lyndra Therapeutics

Series C in 2021
Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

CAMP4 Therapeutics

Series A in 2021
CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Kojin Therapeutics

Series A in 2021
Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

Faro Health

Series A in 2021
Faro Health develops a cloud-based medical platform that standardizes, automates, and streamlines clinical trial processes. Its system handles administrative burdens, allowing clinical researchers to focus on critical decisions that drive clinical value.

Cyclerion Therapeutics

Post in 2021
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing treatments for serious and orphan diseases. The company leverages soluble guanylate cyclase (sGC) pharmacology to create next-generation sGC stimulators. Its pipeline includes Olinciguat, an orally administered vascular sGC stimulator in Phase II studies for sickle cell disease; Praliciguat, another oral sGC stimulator in Phase II trials for diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, a CNS-penetrant sGC stimulator in Phase I trials for neurodegenerative diseases. Additionally, Cyclerion is exploring liver-targeted and lung-targeted sGC stimulators. The company was incorporated in 2018.

Thirty Madison

Series C in 2021
Thirty Madison is a digital health company specializing in personalized treatments for chronic conditions. It operates platforms like Keeps (hair loss), Cove (migraines), Picnic (allergies), Facet (skin conditions), and Nurx (sexual health). Founded in 2016, it aims to empower individuals with accessible, effective care tailored to their specific needs.

August Bioservices

Series A in 2021
August Bioservices, LLC is a contract development and manufacturing organization (CDMO) based in Nashville, Tennessee, with an additional office in Celina, Tennessee. Established in 2017, the company specializes in offering a wide range of services for drug discovery, pharmaceutical development, and clinical manufacturing. Its research services encompass target validation, functional characterization, assay development, drug discovery, protein engineering, and both in vitro and in vivo testing. In the pharmaceutical development arena, August Bioservices provides formulation, process design, optimization, scale-up, and analytical method development. The company's clinical manufacturing capabilities include clinical trial supply, cGMP non-sterile and bulk manufacturing, aseptic fill and finish, and quality control. Additionally, it offers various testing services, such as pregnancy testing and viral disease testing, to clients in the pharmaceutical and biotechnology sectors. August Bioservices was previously known as PMI BioPharma Solutions until its name change in July 2020.

Akili Interactive

Series D in 2021
Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital medicine solutions. The company's core business involves creating video game-based technology to assess and enhance cognitive abilities. Akili's broad pipeline focuses on treating cognitive deficiencies and improving symptoms associated with various medical conditions, such as ADHD, MDD, ASD, and inflammatory diseases.

Engine Biosciences

Series A in 2021
Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

PathAI

Series C in 2021
PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Hummingbird Bioscience

Series C in 2021
Hummingbird Bioscience employs systems biology to uncover disease mechanisms and uses computational platforms for discovering and engineering innovative biotherapeutics. Its pipeline includes HMBD-001 (anti-HER3 antibody) and HMBD-002 (anti-VISTA antibody), both in cancer treatment. The company collaborates strategically with Cancer Research UK and Amgen.

Dyno Therapeutics

Series A in 2021
Founded in 2018, Dyno Therapeutics specializes in developing adeno-associated virus (AAV) vectors for in vivo gene therapy delivery. The company's proprietary platform combines DNA synthesis of AAV capsids with sequencing and machine learning to create novel vectors tailored for safe, efficient, and targeted therapeutic solutions.

Invivyd

Series C in 2021
Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

Tectonic Therapeutic

Series A in 2021
Tectonic Therapeutic is a biotechnology company dedicated to advancing the discovery of novel drugs targeting G Protein-Coupled Receptors (GPCRs), historically considered challenging therapeutic targets. The company's proprietary platform, GEODe, enables the development of biologic medicines aimed at modifying disease progression in areas with significant unmet medical needs.

Cohere Health

Series B in 2021
Founded in 2019 and based in Boston, Cohere Health is a healthcare technology company dedicated to enhancing efficiency and effectiveness within the healthcare system. It achieves this by leveraging technology to simplify processes, improve communication among stakeholders, and ultimately optimize patient outcomes.

Volastra

Seed Round in 2021
Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Tausight

Series A in 2021
Founded in 2018, Tausight is a technology company based in Sudbury, Massachusetts with an additional office in San Francisco. It specializes in developing software to reduce healthcare cyber incidents involving patient data theft.

Amunix

Series B in 2021
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Egenesis

Series C in 2021
Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Armorblox

Series B in 2021
Armorblox, Inc. is a cybersecurity company founded in 2017 and based in Cupertino, California. It specializes in developing data security solutions that focus on protecting the human layer within organizations. Utilizing advanced machine learning and artificial intelligence techniques, Armorblox addresses identity-based attacks and data loss, providing comprehensive security for its clients. The company's innovative approach aims to enhance overall data protection and safeguard sensitive information in an increasingly complex digital landscape.

Livara Health

Series A in 2021
Livara Health specializes in non-invasive, personalized treatment for musculoskeletal conditions. Its platform offers a data-driven six-week program for back pain relief, customized based on patient assessment, along with coaching support.

Folx Health

Series A in 2021
Folx Health is a Boston-based telehealth platform founded in 2020, specializing in digital healthcare services tailored for the LGBTQIA+ community. It offers access to queer and trans clinicians, focusing on gender-affirming hormone therapy, sexual health, and family creation services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.